Previous 10 | Next 10 |
DUBLIN and SOUTH SAN FRANCISCO, Calif. , June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective me...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 05/14/2020. Please visit our Tracking Seth Klarman’s Baupost Group Holding...
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q1 2020 Earnings Call May 8, 2020 , 11:30 p.m. ET Operator Continue reading
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Theravance Biopharma, Inc. (TBPH) Q1 2020 Results Conference Call May 06, 2020 05:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Philip Worboys - Senior Vice President, Research and Translational Scien...
Theravance Biopharma (NASDAQ: TBPH ): Q1 GAAP EPS of -$1.40 misses by $0.33 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , May 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter ended March 31, 2020 . Revenue for the first quarter 2020 was $19.9 million . Operating loss was $72.5 ...
DUBLIN , April 28, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2020 financial results and prov...
Theravance Biopharma (NASDAQ: TBPH ) doses first healthy volunteer in Phase 1 study of TD-0903 . TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19. More news on: ...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , April 23, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-select...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...